secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVELATION BIOSCIENCES, INC. (REVB)
CIK:        0001810560
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001193125-26-212064
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revelation Biosciences Q1 net loss $3.0M; cash $14.1M; FDA agrees to adaptive Phase 2/3 study
--------------------------------------------------------------------------------

- Net loss $3.0M ($2.71/share) vs $2.1M ($25.34/share) in Q1 2025; operating cash burn $3.2M.
- Cash and equivalents $14.1M at March 31, 2026, up from $10.7M at Dec 31, 2025; cash runway through Q1 2027.
- FDA agreed to a single adaptive Phase 2/3 study design for Gemini in acute kidney injury patients.
- Received $6.7M net proceeds from January 2026 warrant inducement.
- Presented positive additional data analysis from PRIME Study at AKI & CRRT 2026 conference.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810560/000119312526212064/0001193125-26-212064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810560/000119312526212064/revb-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-212064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer